Drive payer submission readiness for your Phase 2 and 3 products
Understanding and adapting to evolving payer requirements is becoming increasingly important to managing market access risk and delivering commercial success. Rapid developments in the treatment landscape present new challenges for payers who have different perspectives on value and approaches to market access, while manufacturers are under pressure to bring products to market quickly.
Provides a robust situational analysis based on a consistent and systemized framework that rates your current evidence generation activities against the individual requirements from payer submission templates relevant to your asset
Presents a comprehensive summary of the evidence gaps with a red-amber-green rating of potential challenges, encouraging early clear and consistent communication across the organization
Accelerates HTA submission readiness by producing a high-quality evidence generation plan driven by informed, collaborative, and integrated decision-making
Identifies clear responsibilities across global, regional and affiliates for implementation, recognizing that not all gaps can or will be bridged
Top-10 pharmaceutical and biotechnology manufacturers have transformed their strategic market access processes with the PRMA Healthcheck® late module.
How are digital applications transforming the value and access functions?
Pharmaceutical and biotechnology companies are turning to technology more frequently to solve business issues, and are increasingly using digital technology to optimize market access for their products. We believe that there are three key benefits for market access.
A consumate piece of analysis with astute outputs, I look forward to making good use of it.
The work culminated in a very successful early launch meeting with live market feedback and sharing of early global strategy.
Request a demonstration
Our user friendly applications and expert team have supported organizations around the world in achieving their goals. We are always happy to have an informal, confidential chat and help you re-think your market access challenges.